South Korea’s Shift to Insurance Coverage for Epidural Neuroplasty Raises Concerns Over Patient Choice and Care Quality
Seoul, South Korea — A recent policy change in South Korea’s national health insurance system is sparking debate among medical professionals, policymakers, and patient advocacy groups. The country’s Health Insurance Review and Assessment Service (HIRA) has reclassified epidural neuroplasty—a minimally invasive procedure for chronic back pain—as a managed insurance benefit, a move critics argue could limit patient access to alternative treatments and strain hospital finances. Experts at a recent academic conference warned that the decision, while intended to standardize care, may inadvertently reduce treatment options and compromise quality.
Epidural neuroplasty, similarly known as epidural adhesiolysis or the Racz procedure, is a specialized intervention for patients with chronic spinal pain caused by scar tissue or inflammation around nerve roots. Traditionally, the procedure was available in South Korea as a non-insured service, meaning patients paid out-of-pocket or relied on private insurance. Under the new policy, effective April 1, 2026, the procedure is now covered by the national health insurance system—but only under strict conditions, including prior authorization and adherence to standardized protocols. While proponents argue the change will reduce financial burdens on patients, medical professionals at the 2026 Korean Policy Studies Spring Conference raised concerns that the shift could backfire, particularly for middle- and low-income patients who may now face longer wait times or limited access to tailored care.
“The transition to managed insurance coverage for epidural neuroplasty is a double-edged sword,” said Dr. Kim Chang-soo, a professor of health policy at Yonsei University College of Medicine and a speaker at the conference. “While it improves affordability for some, it also introduces rigid guidelines that may not account for individual patient needs. The risk is that we trade financial accessibility for clinical flexibility—and that’s a trade-off that could harm patients in the long run.” Dr. Kim’s remarks echo broader concerns in South Korea’s healthcare system, where rapid policy shifts have historically struggled to balance cost control with patient-centered care.
The Policy Shift: What Changed and Why?
The reclassification of epidural neuroplasty as a managed insurance benefit is part of South Korea’s broader effort to expand coverage under its National Health Insurance (NHI) system, one of the world’s most comprehensive single-payer programs. The NHI covers approximately 97% of the population, with the remaining 3% covered by a separate medical aid program for low-income individuals. Historically, the system has excluded certain advanced or specialized procedures from coverage, leaving patients to pay privately or seek alternatives. However, in recent years, the government has pushed to include more treatments under insurance to reduce out-of-pocket costs, which remain among the highest in the OECD relative to household income.
The decision to cover epidural neuroplasty was announced in December 2025 by the Ministry of Health and Welfare (MOHW) and implemented on April 1, 2026. According to the ministry’s official statement, the change aims to “ensure equitable access to evidence-based pain management” and “reduce the financial burden on patients with chronic spinal conditions.” The policy applies to patients diagnosed with lumbar spinal stenosis, failed back surgery syndrome (FBSS), or chronic radiculopathy who have not responded to conservative treatments such as physical therapy or medication.
However, the new guidelines come with significant restrictions. To qualify for insurance coverage, patients must meet the following criteria:
- Diagnosis of a qualifying condition confirmed by MRI or CT imaging.
- Failure to respond to at least 6 weeks of conservative treatment, including medication and physical therapy.
- Prior authorization from HIRA, which requires submission of medical records and imaging results.
- Performance of the procedure by a board-certified pain specialist in a designated medical facility.
Critics argue that these requirements, while intended to prevent overuse, may create barriers for patients who could benefit from the procedure but do not meet the strict criteria. For example, patients with acute exacerbations of chronic pain or those who cannot tolerate prolonged conservative treatment may be denied coverage, forcing them to either pay out-of-pocket or seek less effective alternatives.
Concerns Over Treatment Choice and Quality of Care
The primary concern raised by medical professionals is that the policy could narrow patient choice by funneling individuals toward a single, standardized treatment pathway. In a panel discussion at the 2026 Korean Policy Studies Spring Conference, held in Seoul on April 24, 2026, experts warned that the shift to managed insurance coverage could lead to a “one-size-fits-all” approach that fails to account for the complexity of chronic pain management.
“Chronic pain is not a monolithic condition,” said Dr. Park Hyeong-wook, a professor of anesthesiology and pain medicine at Dankook University College of Medicine and a co-panelist at the conference. “Some patients respond well to epidural neuroplasty, while others may benefit more from physical therapy, nerve blocks, or even surgical intervention. By making this procedure the ‘default’ covered option, we risk sidelining other evidence-based treatments that could be more appropriate for certain patients.”
Dr. Park’s concerns are supported by international research on pain management. A 2023 systematic review published in the Journal of Pain Research found that while epidural neuroplasty can be effective for select patients, its success rates vary widely depending on the underlying condition, patient age, and duration of symptoms. The study concluded that “individualized treatment plans, rather than protocol-driven approaches, yield the best outcomes for chronic pain patients.” (Source: Journal of Pain Research)
Another major concern is the potential for reduced quality of care. Under the new policy, hospitals and clinics performing epidural neuroplasty must adhere to strict reporting requirements, including documentation of patient outcomes, complication rates, and adherence to procedural protocols. While these measures are designed to ensure safety and efficacy, some experts fear they could discourage smaller or less-resourced facilities from offering the procedure altogether.
“The administrative burden of compliance is significant,” said Dr. Oh Young-ah, a professor of health policy at National Medical Center and another speaker at the conference. “Smaller clinics, particularly in rural areas, may find it difficult to meet the new requirements, which could lead to a concentration of services in large urban hospitals. This would exacerbate existing disparities in access to care, particularly for patients outside major cities.”
Financial Strain on Hospitals and the Risk of “Race to the Bottom”
Beyond patient care, the policy change has raised alarms about its financial impact on hospitals, particularly small and medium-sized facilities. Under South Korea’s fee-for-service reimbursement model, the NHI sets fixed prices for covered procedures, which are often lower than the rates hospitals could charge for non-insured services. For epidural neuroplasty, the reimbursement rate was set at ₩1.2 million (approximately $900 USD) per procedure, a figure that some hospital administrators argue is insufficient to cover costs, particularly in private or semi-private facilities.
The Korean Hospital Association (KHA) has warned that the low reimbursement rate could lead to a “race to the bottom”, where hospitals cut corners to maintain profitability. In a March 2026 statement, the KHA noted that the reimbursement rate does not account for the high cost of specialized equipment, such as fluoroscopy machines, or the additional staffing required for post-procedural monitoring. The association called for a “re-evaluation of the reimbursement structure” to prevent unintended consequences, including reduced service availability or lower-quality care.
“We understand the government’s goal of expanding coverage, but the current reimbursement rate does not reflect the true cost of providing this service,” said Lee Sang-woon, president of the Korean Hospital Association. “If hospitals are forced to operate at a loss, they may stop offering the procedure entirely, which would defeat the purpose of the policy.”
The financial strain is particularly acute for middle-tier hospitals, which often serve as a bridge between large academic medical centers and small community clinics. These facilities, which account for roughly 40% of South Korea’s hospital beds, play a critical role in providing specialized care to underserved populations. However, they operate on thinner margins than larger hospitals and may lack the resources to absorb the financial hit from lower reimbursement rates.
Calls for a More Nuanced Approach
In response to the growing backlash, some experts are calling for a more flexible and collaborative approach to integrating epidural neuroplasty into the NHI system. At the 2026 Korean Policy Studies Spring Conference, several speakers proposed alternatives to the current policy, including:
- Tiered coverage models: Offering partial insurance coverage for patients who do not meet all criteria but could still benefit from the procedure, with the remainder covered by private insurance or out-of-pocket payments.
- Regional pilot programs: Testing the policy in select regions before nationwide implementation to assess its impact on patient outcomes and hospital finances.
- Stakeholder engagement: Involving patient advocacy groups, medical societies, and hospital administrators in ongoing policy discussions to refine the guidelines.
- Performance-based reimbursement: Adjusting reimbursement rates based on patient outcomes and complication rates, rather than a fixed fee.
“The key is to avoid a top-down, one-size-fits-all approach,” said Dr. Kim Yu-il, a professor of health economics at Chonnam National University College of Medicine and a panelist at the conference. “Policies like this should be iterative, with built-in mechanisms for feedback and adjustment. Otherwise, we risk creating more problems than we solve.”
Dr. Kim’s call for flexibility is echoed by international examples. In the United States, for instance, the Centers for Medicare & Medicaid Services (CMS) has experimented with value-based payment models for pain management procedures, which tie reimbursement to patient outcomes rather than volume. Similarly, the United Kingdom’s National Health Service (NHS) has adopted shared decision-making tools to help patients and providers choose the most appropriate treatment for chronic pain, rather than defaulting to a single covered option. (Source: CMS Value-Based Programs)
What’s Next for Patients and Providers?
As of April 2026, the policy is in its early stages of implementation, and its full impact remains to be seen. The Ministry of Health and Welfare has indicated that it will monitor the policy’s effects over the next 12 months, with a formal review scheduled for April 2027. In the meantime, patients and providers are adjusting to the new landscape, with some hospitals already reporting delays in scheduling due to the prior authorization process.
For patients, the change underscores the importance of advocating for individualized care. Those considering epidural neuroplasty should:
- Consult with a board-certified pain specialist to determine if they meet the insurance criteria.
- Discuss alternative treatments, such as nerve blocks, radiofrequency ablation, or physical therapy, which may be more appropriate for their condition.
- Check with their insurance provider to understand out-of-pocket costs and coverage limitations.
For hospitals, the policy presents both challenges and opportunities. While the financial pressures are real, some facilities are using the change as an opportunity to streamline operations and improve patient education. For example, Seoul National University Hospital has launched a dedicated pain management clinic to help patients navigate the new insurance requirements and explore all available treatment options.
“The goal should always be to put the patient first,” said Dr. Lee Ji-eun, a pain specialist at Seoul National University Hospital. “If this policy helps more patients access care, that’s a positive outcome. But if it limits their choices or forces them into treatments that aren’t right for them, then we’ve missed the mark.”
Key Takeaways
- Policy Change: South Korea’s national health insurance now covers epidural neuroplasty as a managed benefit, effective April 1, 2026, but with strict eligibility criteria and prior authorization requirements.
- Patient Concerns: Critics argue the policy could limit treatment choices, particularly for patients who do not meet the strict criteria or who may benefit from alternative therapies.
- Quality of Care: Experts warn that rigid guidelines could lead to a “one-size-fits-all” approach, potentially reducing the effectiveness of pain management for some patients.
- Financial Impact: Hospitals, particularly smaller facilities, may struggle with the low reimbursement rate, which could lead to reduced service availability or lower-quality care.
- Calls for Flexibility: Medical professionals and policymakers are advocating for a more nuanced approach, including tiered coverage models and stakeholder engagement.
- Next Steps: The Ministry of Health and Welfare will review the policy’s impact in April 2027, with ongoing monitoring in the interim.
FAQ
What is epidural neuroplasty?
Epidural neuroplasty, also known as epidural adhesiolysis or the Racz procedure, is a minimally invasive procedure used to treat chronic back pain caused by scar tissue or inflammation around spinal nerve roots. It involves the injection of medications and the use of a catheter to break up adhesions and reduce inflammation.
Who qualifies for insurance coverage under the new policy?
To qualify for insurance coverage, patients must have a confirmed diagnosis of lumbar spinal stenosis, failed back surgery syndrome, or chronic radiculopathy, and must have failed to respond to at least 6 weeks of conservative treatment. They must also obtain prior authorization from HIRA and have the procedure performed by a board-certified pain specialist in a designated facility.
What are the concerns about the new policy?
The primary concerns are that the policy could limit patient choice by funneling individuals toward a single treatment pathway, reduce the quality of care due to rigid guidelines, and strain hospital finances due to low reimbursement rates. Critics also worry that smaller hospitals may stop offering the procedure, reducing access for patients in rural areas.
How does this policy compare to other countries?
Many countries, including the United States and the United Kingdom, have adopted more flexible approaches to pain management, such as value-based payment models or shared decision-making tools. These models prioritize individualized care and tie reimbursement to patient outcomes, rather than imposing strict, protocol-driven guidelines.
What can patients do if they don’t qualify for insurance coverage?
Patients who do not meet the insurance criteria may still be able to access epidural neuroplasty through private insurance or out-of-pocket payments. They should consult with a pain specialist to explore alternative treatments, such as nerve blocks, radiofrequency ablation, or physical therapy.
What’s next for the policy?
The Ministry of Health and Welfare will monitor the policy’s impact over the next 12 months, with a formal review scheduled for April 2027. In the meantime, patients and providers are encouraged to provide feedback to help refine the guidelines.
As South Korea navigates this latest shift in its healthcare system, the debate over epidural neuroplasty coverage highlights the broader challenges of balancing cost control, patient access, and quality of care. For now, patients and providers alike are watching closely to see how the policy unfolds—and whether it will deliver on its promise of equitable, evidence-based pain management.
What are your thoughts on South Korea’s approach to managing chronic pain treatments? Should insurance systems prioritize flexibility or standardization? Share your comments below and join the conversation on how healthcare policies can better serve patients.